Filing Overview
Clover Health Investments, Corp. filed a Form 8-K under Item 5.02 regarding a change in executive leadership. The filing identifies January 13, 2022 as the report date, but the disclosed events and signature date are January 19, 2022.
Executive Change and Compensation
- Gia Lee stepped down as the Company’s General Counsel and an officer effective January 19, 2022.
- Ms. Lee stated that her departure was not due to any disagreement with the Company regarding its operations, policies, or practices.
- Karen Soares, Deputy General Counsel, became Interim General Counsel pending a search for a permanent replacement.
- Under a separation agreement, subject to customary conditions including a release of claims, Ms. Lee will receive a lump sum comprising:
- $520,000, described as 12 months of base salary plus the prior-year bonus;
- $120,000 in lieu of her 2021 bonus; and
- $700,000 as a special cash bonus recognizing services related to the January 7, 2021 de-SPAC transaction.
- The disclosed lump-sum amounts total $1.34 million.
- Ms. Lee will provide consulting services for up to 12 months at $10,000 per month, potentially adding up to $120,000 if the full period is completed.
- Previously granted stock options will continue to vest during the consulting period, subject to continued service and the applicable equity plan documents.
- Certain termination circumstances may trigger payment of remaining consulting fees and acceleration of eligible unvested options.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, or other operating metrics. It also does not clearly state the accounting treatment or timing of the separation-related payments.
Material Changes and Outlook
The material change is the departure of the General Counsel and appointment of an interim successor. Management characterized Ms. Lee’s departure positively and did not disclose an operational disagreement, disruption, or change to financial outlook. The Company has initiated a search for a permanent General Counsel.
Risks and Unusual Items
- The separation agreement creates disclosed cash obligations of $1.34 million, plus potential consulting fees and additional amounts depending on the consulting-period termination circumstances.
- Continued option vesting and possible acceleration could create additional equity-based compensation or dilution; the filing does not quantify the affected options.
- The filing states that the agreement summary is not complete. The full agreement is expected to be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Investor Verification Items
- Verify the effective date and reconcile the filing’s January 13 report date with the January 19 announcement and signature dates.
- Review the full separation agreement in the subsequent Form 10-K for payment conditions, termination provisions, consulting obligations, and option treatment.
- Determine the number and value of stock options subject to continued vesting or potential acceleration.
- Assess the final accounting impact of the separation payments, consulting fees, and equity-related obligations.
- Monitor the appointment of a permanent General Counsel and any related changes in corporate governance or risk management.